Display options
Cite
Refsgaard LK, Haubro K, Pickering DS, et al. Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. Psychopharmacology (Berl). 2016;233(21):3763-3770doi: 10.1007/s00213-016-4407-6.
Refsgaard, L. K., Haubro, K., Pickering, D. S., Stuart, S. A., Robinson, E. S., & Andreasen, J. T. (2016). Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. Psychopharmacology, 233(21), 3763-3770. https://doi.org/10.1007/s00213-016-4407-6
Refsgaard, Louise K, et al. "Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test." Psychopharmacology vol. 233,21 (2016): 3763-3770. doi: https://doi.org/10.1007/s00213-016-4407-6
Refsgaard LK, Haubro K, Pickering DS, Stuart SA, Robinson ES, Andreasen JT. Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. Psychopharmacology (Berl). 2016 Oct;233(21):3763-3770. doi: 10.1007/s00213-016-4407-6. Epub 2016 Aug 30. PMID: 27572627.
Copy Download .nbib Format: NLM
Share it on

Psychopharmacology (Berl). 2016 Oct;233(21):3763-3770. doi: 10.1007/s00213-016-4407-6. Epub 2016 Aug 30.

Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test.

Psychopharmacology

Louise K Refsgaard, Kia Haubro, Darryl S Pickering, Sarah A Stuart, Emma S J Robinson, Jesper T Andreasen

Affiliations

  1. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100, Copenhagen, Denmark.
  2. School of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Bristol, UK.
  3. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100, Copenhagen, Denmark. [email protected].

PMID: 27572627 DOI: 10.1007/s00213-016-4407-6

Abstract

RATIONALE: Affective biases seemingly play a crucial role for the onset and development of depression. Acute treatment with monoamine-based antidepressants positively influences emotional processing, and an early correction of biases likely results in repeated positive experiences that ultimately lead to improved mood.

OBJECTIVES: Using two conventional antidepressants, sertraline and duloxetine, we aimed to forward the characterization of a newly developed affective bias test (ABT) for rats. Further, we examined the effect of vortioxetine, a recently approved antidepressant, and the α

METHODS: Sprague Dawley rats were tested in an affective bias test using a fully balanced within-subject study design. Rats learned to associate two different digging substrates with a reward during six reward-pairing days. The absolute value of the rewards was identical, but the affective state at the time of learning induces a positive or negative bias towards the treatment-paired digging substrate at recall. The choice bias between the two digging substrates at recall represents the affective bias. Sertraline (1, 3 and 10 mg/kg), duloxetine (1, 3 and 10 mg/kg), vortioxetine (1, 3 and 10 mg/kg) and idazoxan (3 and 10 mg/kg) were tested in the ABT.

RESULTS AND CONCLUSIONS: All four drugs, regardless of their mechanism of action, induced a positive affective bias in the ABT, although the overall effect of treatment was not statistically significant for sertraline and duloxetine. The largest effects were induced by vortioxetine and idazoxan, both of which caused significant positive biases at all tested doses.

Keywords: Affective bias; Antidepressant; Cognition; Depression; Emotional processing

References

  1. J Affect Disord. 1999 Dec;56(2-3):237-43 - PubMed
  2. Am J Psychiatry. 2004 Jul;161(7):1256-63 - PubMed
  3. Schizophr Res. 2009 Feb;107(2-3):206-12 - PubMed
  4. Neuropsychopharmacology. 2013 Aug;38(9):1625-35 - PubMed
  5. Am J Psychiatry. 2009 Oct;166(10):1178-84 - PubMed
  6. J Psychopharmacol. 2012 Nov;26(11):1408-16 - PubMed
  7. Am J Psychiatry. 2003 May;160(5):990-2 - PubMed
  8. J Abnorm Psychol. 2004 Feb;113(1):121-35 - PubMed
  9. J Affect Disord. 2006 Apr;91(2-3):243-50 - PubMed
  10. Int Clin Psychopharmacol. 2003 Jan;18(1):9-14 - PubMed
  11. Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533 - PubMed
  12. Neuropsychopharmacology. 2003 Jan;28(1):148-52 - PubMed
  13. Xenobiotica. 1988 May;18(5):519-32 - PubMed
  14. Neuropsychopharmacology. 2015 Aug;40(9):2165-74 - PubMed
  15. Psychopharmacology (Berl). 1995 Aug;120(4):409-17 - PubMed
  16. J Psychopharmacol. 2000 Jun;14(2):114-38 - PubMed
  17. Nat Rev Neurosci. 2011 Jul 06;12 (8):467-77 - PubMed
  18. Psychiatry Res. 1992 Jun;42(3):241-51 - PubMed
  19. J Neurochem. 1997 Dec;69(6):2616-9 - PubMed
  20. Psychopharmacology (Berl). 2008 Sep;199(4):495-502 - PubMed
  21. Behav Brain Res. 2004 Dec 6;155(2):275-82 - PubMed
  22. Pharmacol Biochem Behav. 2013 Apr;105:41-50 - PubMed
  23. J Psychopharmacol. 2004 Sep;18(3):395-403 - PubMed
  24. Biol Psychol. 2002 Sep;60(2-3):79-90 - PubMed
  25. Arch Gen Psychiatry. 1989 Oct;46(10):958-9 - PubMed
  26. Neurosci Biobehav Rev. 2012 Nov;36(10):2214-25 - PubMed
  27. J Psychiatr Res. 2003 Mar-Apr;37(2):99-108 - PubMed
  28. Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600 - PubMed
  29. Depress Res Treat. 2014;2014:627863 - PubMed
  30. Neuropsychopharmacology. 2015 Jul;40(8):2025-37 - PubMed
  31. Biochem Pharmacol. 1984 Aug 15;33(16):2553-7 - PubMed
  32. J Pharmacol Exp Ther. 2012 Mar;340(3):666-75 - PubMed
  33. Curr Top Behav Neurosci. 2013;14:209-22 - PubMed
  34. Neuroscience. 2015 Mar 19;289:262-9 - PubMed
  35. Psychopharmacology (Berl). 2009 May;203(4):685-91 - PubMed
  36. Br J Psychiatry. 2009 Aug;195(2):102-8 - PubMed
  37. J Psychiatr Res. 2009 Jun;43(9):855-63 - PubMed
  38. Life Sci. 1993;52(12):1023-9 - PubMed
  39. Biol Psychiatry. 2005 May 15;57(10):1089-96 - PubMed
  40. Am J Physiol. 1991 Jan;260(1 Pt 2):R142-7 - PubMed
  41. Br J Psychiatry. 2009 Jun;194(6):535-40 - PubMed
  42. Curr Med Res Opin. 2014 Dec;30(12):2589-606 - PubMed
  43. Am J Psychiatry. 2007 Jun;164(6):900-9 - PubMed
  44. J Clin Psychiatry. 2002 May;63(5):396-402 - PubMed
  45. Neuropharmacology. 2013 Oct;73:147-59 - PubMed
  46. Br J Pharmacol. 1993 Jul;109(3):655-60 - PubMed
  47. J Pharmacol Exp Ther. 2011 Aug;338(2):605-14 - PubMed
  48. Drug Metab Dispos. 1989 Sep-Oct;17(5):542-50 - PubMed
  49. Behav Brain Res. 2011 Jun 20;220(1):83-90 - PubMed
  50. Int Clin Psychopharmacol. 2012 Jul;27(4):215-23 - PubMed
  51. Br J Pharmacol. 2014 Oct;171(20):4524-38 - PubMed
  52. Int J Geriatr Psychiatry. 2012 Aug;27(8):777-84 - PubMed
  53. Neuropsychopharmacology. 1995 Jul;12(4):287-95 - PubMed
  54. Psychol Med. 2007 Sep;37(9):1281-91 - PubMed

Substances

MeSH terms

Publication Types

Grant support